hi anyone know anything about this
Orphan Drug Designation in European Union for GLP1690 For Idiopathic Pulmonary Fibrosis
today (6 sept 2016) at 16:30 CET hours
Galapagos is presenting
Strong reversal of the lung fibrosis disease signature by autotaxin inhibitor GLPG1690 in a mouse model for IPF
at the European respiratory Society Congress in London .
GLPG1690 is currently being evaluated in the FLORA study Phase two clinical trial . top line data by mid 2017
clinical trial NCT02738801